Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830485) titled 'CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
Multiple Myeloma
Intervention:
Drug: CM336 (BCMA/CD3 bispecific antibody)
Drug: Daratumumab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 15, 2026
Target Sample Size: 24
Countries of Recruitment:
China
To know mor...